Strengthening Replication and Reproducibility of NIH-funded Research
NIH is launching a new, agency-wide initiative to elevate replication and reproducibility studies as foundational to the conduct of gold standard science. Driving and sustaining culture change will take ideas from and […]
Rural communities face unique challenges in accessing HIV services, but support is available. This blog post offers practical tips for getting tested, engaging in care, and using telehealth to overcome distance-related barriers. […]
The 2026 CHIPTS HIV Next Generation Conference welcomed over 150 attendees from academic institutions, community-based organizations, health care institutions, and other organizations working to end the HIV […]
NIH has implemented steps towards a unified strategy that will help guide clearer and consistent funding decisions across all Institutes, Centers, and Offices (ICOs). […]
CHIPTS continues to use our website and social media accounts to disseminate the latest developments in HIV research, enriching learning opportunities, Center news, and more […]
This World AIDS Day arrives at a moment of profound uncertainty. The global architecture that sustained HIV prevention and care for decades is shifting beneath us. The loss of PEPFAR and USAID funding, coupled with […]
A spotlight featuring the three projects of our 2025 CHIPTS Rapid Projects awardees that includes project titles and project abstracts. Dr. Wei-Ti Chen tests a compassion-based intervention to reduce stigma and improve mental health. Dr. Huyen Pham uses evidence synthesis and […]
Centers for Disease Control and Prevention (CDC) published new Clinical Recommendations for twice-a-year injectable lenacapavir as an additional option for HIV prevention in the United States. The U.S. Food and Drug Administration approved injectable lenacapavir […]
UNAIDS welcomes the announcement by the US State Department that the President’s Emergency Plan for […]
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir)—the company’s injectable HIV-1 […]